benzinga.comSEP 183 min read$ILMN

Illumina Reports Q2 2026 Results: Full Earnings Call Transcript - Illumina (NASDAQ:ILMN)

Illumina (ILMN) reported Q2 2026 revenue growth of 9.5% YoY and EPS growth of 10%, driven by strong demand for NovaSeq X. The company raised its 2026 guidance, expecting full-year organic revenue growth over 5% and mid-teens growth in clinical consumables. Strategic initiatives include expanding multi-omics capabilities and strengthening the BioInsight platform. Management emphasized cost management and confidence in long-term targets.

Original reporting

benzinga.com

Published Sep 18, 2026, 8:37 AM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Sep 18, 2026, 9:26 AM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

AlphAI market briefEarnings

Primary signal

$ILMN

Bullish

high confidence

Mentioned

$ILMN

Relevance

8/10

AlphAI data visualization · based on benzinga.com

Decision brief

The 30-second read

$ILMNBullishHigh

Why it matters

The earnings beat and guidance raise are likely to drive buying interest, especially given the company's leadership in sequencing technology.

Market read

Illumina's results are a key catalyst for the biotech sequencing sector and may affect related stocks and ETFs.

What to watch

Rising memory and freight costs could pressure margins if not managed.

Relevance 8/10Novelty 8/10Timing: Q2 2026 earnings released after market close

Background

Illumina's Q2 2026 earnings call provides the first public disclosure of quarterly results and updated guidance.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$ILMNBullishHigh confidence

Context

Illumina reported Q2 2026 earnings with 9.5% revenue growth, EPS up 10% and raised full-year guidance.

Expected impact

Potential short‑term price rally as investors price in higher revenue growth and guidance.

Evidence & confidence

Earnings beat and guidance raise are fresh primary disclosures that typically move the stock on the day of release.

Market effects

Sector

Positive momentum for the genomics sequencing sector as Illumina's growth signals demand for sequencing platforms.

Regional

U.S. and Canada clinical markets see reinforced demand, supporting regional biotech equities.

Global

Illumina's multi‑omics expansion may influence global biotech investment themes.

Counterpoint

What could challenge this read

If the guidance raise is already priced in, the stock may face a pull‑back on profit‑taking.

Key entities

Executive
Jacob Tyson
CEO of Illumina, presented earnings highlights.
Executive
Ankur Dhingra
CFO of Illumina, presented financial details.

Read at source ← All news

OCT 13

$ILMNMed

Illumina Launches $1.0 Billion Unsecured Commercial Paper Program; Signs Dealer Agreements

Illumina established a $1.0 billion unsecured commercial paper program for general corporate purposes. The program allows short-term notes with maturities up to 397 days. A national bank will serve as the issuing and paying agent, with three dealers initially participating. No notes were outstanding as of the filing date.

tradingview.com1 min

OCT 5

$ILMNMed

Illumina (ILMN) Shares Skyrocket, What You Need To Know

Illumina (ILMN) shares rose 7.7% after analysts raised price targets, citing expected clinical sales growth and AI applications. The stock closed at $293.84, up 7.6%. Illumina's shares have seen significant volatility, with a 22.4% gain last year on strong earnings. The company has raised its full-year EPS guidance to $4.70. ILMN is up 119% YTD, reaching a 52-week high.

financialcontent.com2 min

SEP 24

$ILMNHighAI 8/10

Illumina Soars to New High After Index Win

Illumina (ILMN) shares hit a 52-week high after being added to the S&P 500 Equal Weighted Index. The company announced a $300M note offering, strong earnings, and raised full-year guidance. Analysts increased price targets, citing sustainable earnings and clinical sequencing demand. The stock's rise is driven by index inclusion, debt refinancing, and upgraded guidance, with future growth expected from its sequencer business model.

tipranks.com2 min

SEP 23

$GRALMed

This test screens for 50 cancers - but whether Medicare and other health insurers will cover it hinges on FDA approval

Grail's Galleri test, which screens for 50 cancers, is under FDA review for approval. A major study failed to prove it detects later-stage cancers, causing skepticism among doctors. Grail's stock dropped 50% on the news but has since rebounded. FDA approval could lead to insurance coverage and impact competitors like Caris Life Sciences and Guardant Health.

morningstar.com6 min

SEP 18

$ILMNHighAI 8/10

Illumina Q2FY26 Results: Revenue up 9.5% to $1.16 billion

Illumina reported Q2 2026 revenue of $1.16B, up 9.5% YoY, driven by NovaSeq X demand and clinical consumables growth. Non-GAAP EPS rose 10% to $1.31. The company raised full-year guidance, projecting revenue of $4.60B-$4.64B and EPS of $5.30-$5.40. Management cited strong instrument placements and cost management despite rising expenses. Illumina repurchased 0.9M shares and holds $1.17B in cash. The stock has returned 13.26% annually over 20 years, outperforming the market by 3.84%.

scanx.trade3 min

SEP 17

$ILMNMedAI 9/10

There's a biotech stock on Josh Brown's list that's ignoring the market noise and pushing higher

Illumina (ILMN) stock has risen 160% from its October 2025 low, defying broader market trends. The genomics company reported Q2 revenue of $1.16B, up 9.5% YoY, and raised full-year guidance. The stock is up 74.5% YTD and will be added to the S&P 500. Analysts note its strong technical performance and relative strength.

cnbc.com3 min